Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Chronis (Ioannina, Greece), C. Kyriakopoulos (Ioannina, Greece), E. Papapetrou (Ioannina, Greece), C. Tsaousi (Ioannina, Greece), A. Tatsioni (Ioannina, Greece), A. Gogali (Ioannina, Greece), C. Katsanos (Ioannina, Greece), K. Vaggeli (Ioannina, Greece), V. Bellou (Ioannina, Greece), M. Kosta (Ioannina, Greece), A. Spanou (Ioannina, Greece), C. Tselepi (Ioannina, Greece), A. Charisis (Ioannina, Greece), G. Daskalopoulos (Ioannina, Greece), S. Constantopoulos (Ioannina, Greece), K. Kostikas (Ioannina, Greece), A. Konstantinidis (Ioannina, Greece). Endothelial injury in COPD assessed by microalbuminuria (MAB) and von Willebrand factor levels (vWf:Ag) and activity (vWf:Ac). 3313

Member's Comments

No comment yet.

Related content which might interest you: Microalbuminuria and von Willebrand factor antigen (vWF) as markers of endothelial dysfunction in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 123s Year: 2004 Changes of plasma von Willebrand factor in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 138s Year: 2007 Expression of CD 34 and von Willebrand factor in pulmonary endothelium Source: Eur Respir J 2001; 18: Suppl. 33, 243s Year: 2001 PP308 – Endothelial injury in Chronic Obstructive Pulmonary Disease assessed by microalbuminuria (MAB) and von Willebrand factor levels and activity Source: ERS Lung Science Conference 2021 Year: 2021 Diagnostic value of Von Willebrand factor (VWF) in patients suffering from respiratory distress Source: Annual Congress 2011 - Mechanisms of acute lung injury and mesenchymal cell treatment Year: 2011 Response of plasma von Willebrand factor to systemic endothelial injury in pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 545s Year: 2006 Elevated Von Willebrand Factor expression in the activated pulmonary endothelium of chronic thromboembolic pulmonary hypertension patients enhances platelet adhesion. Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Reduced larger von Willebrand factor multimers at dawn in OSA plasmas reflect severity of apnoeic episodes}, Source: Eur Respir J 2012; 40: 657-664 Year: 2012 Endotrophin and von Willebrand factor processing as predictive markers for mortality in the ECLIPSE COPD cohort Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Elevated factor FVIII:C levels in patients with pulmonary hypertension: a marked of endothelial dysfunction? Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 Vascular endothelial growth factor (VEGF) is a predictable marker for FEV1 progression in patients with Lymphangiolyomyomatosis (LAM). Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019 Endothelin, endothelial cells and von Willenbrandt factor in peripheral blood in asthma patients Source: Eur Respir J 2003; 22: Suppl. 45, 77s Year: 2003 Expression of platelet derived-growth factor (PDGF) in remodelled pulmonary arteries of COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 25s Year: 2002 Higher plasma total homocysteine (tHcy) level and abnormal methionine loading test (MLT) in family members of patients with pulmonary embolism (PE) and carriers of factor V Leiden (FVL) Source: Annual Congress 2004 - Pulmonary embolism Year: 2004 Impact of recombinant factor VIIa (rFVIIa) on transfusion related acute lung injury (TRALI) Source: Eur Respir J 2006; 28: Suppl. 50, 180s Year: 2006 Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD Source: Eur Respir J 2005; 26: Suppl. 49, 350s Year: 2005 Arterial concentration of macrophage migration inhibitory factor (MIF) increases with exercise in patients with pulmonary hypertension (PH) Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Expression of bradykinin B2 receptor (B2R) and vascular endothelial growth factor (VEGF) in asthma and COPD Source: Eur Respir J 2007; 30: Suppl. 51, 138s Year: 2007 The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF) Source: Eur Respir J 2004; 24: Suppl. 48, 553s Year: 2004